Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 85,271 Shares

Key Points

• COO Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals stock at an average price of $35.52, totaling over $3 million, which marked a 65.73% decrease in his ownership.
• Shares of Kiniksa Pharmaceuticals traded up 2.4%, reaching $36.57, while the company boasts a market cap of $2.71 billion and has a 52-week high of $36.74.
• Analysts have set a consensus price target of $41.17 for Kiniksa Pharmaceuticals, with multiple firms upgrading their ratings and price targets significantly in recent months.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 85,271 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $35.52, for a total transaction of $3,028,825.92. Following the completion of the transaction, the chief operating officer directly owned 44,452 shares in the company, valued at $1,578,935.04. This trade represents a 65.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Eben Tessari also recently made the following trade(s):

• On Friday, September 5th, Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.66, for a total transaction of $477,451.74.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.50, for a total value of $535,730.50.
• On Monday, August 18th, Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.77, for a total value of $547,074.00.
• On Tuesday, August 5th, Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.20, for a total value of $4,601,984.80.
• On Monday, July 14th, Eben Tessari sold 18,900 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $28.72, for a total value of $542,808.00.
• On Monday, June 16th, Eben Tessari sold 17,300 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $28.28, for a total value of $489,244.00.
• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.51, for a total value of $1,374,231.42.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.46, for a total value of $472,312.76.

Kiniksa Pharmaceuticals International Trading Up 0.2%

NASDAQ KNSA traded up $0.09 during trading on Friday, hitting $37.10. 396,031 shares of the company traded hands, compared to its average volume of 411,524. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $37.34. The business has a fifty day simple moving average of $31.86 and a 200 day simple moving average of $27.08. The company has a market capitalization of $2.75 billion, a P/E ratio of 927.73 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on KNSA. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 7th. Finally, Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $41.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. bought a new position in Kiniksa Pharmaceuticals International during the second quarter worth about $31,000. Tower Research Capital LLC TRC lifted its stake in Kiniksa Pharmaceuticals International by 1,539.1% during the second quarter. Tower Research Capital LLC TRC now owns 25,275 shares of the company's stock worth $699,000 after purchasing an additional 23,733 shares during the period. Rubric Capital Management LP lifted its stake in Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock worth $108,184,000 after purchasing an additional 526,567 shares during the period. Lazard Asset Management LLC lifted its stake in Kiniksa Pharmaceuticals International by 428.8% during the second quarter. Lazard Asset Management LLC now owns 15,181 shares of the company's stock worth $420,000 after purchasing an additional 12,310 shares during the period. Finally, Engineers Gate Manager LP bought a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth about $1,640,000. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.